Squarepoint
INBX icon

Squarepoint’s Inhibrx INBX Stock Holding History

Squarepoint’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620K Sell
6,543
-9,096
-58% -$911K ﹤0.01% 3256
2026
Q1 		$1.05M Buy
15,639
+12,241
+360% +$908K ﹤0.01% 2738
2025
Q4 		$268K Buy
+3,398
New +$232K ﹤0.01% 3685
2024
Q4 		– Sell
-21,066
Closed -$330K – 5246
2024
Q3 		$330K Buy
+21,066
New +$296K ﹤0.01% 3385

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's INBX Position: Q2 2026 in Review

Squarepoint reduced its Inhibrx (INBX) stake by 58% in Q2 2026, selling an estimated $911K and leaving 6,543 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Squarepoint first reported a position in INBX in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.05M in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Squarepoint held 6,543 shares of Inhibrx worth $620K as of Q2 2026.
  • Squarepoint sold 9,096 Inhibrx shares in Q2 2026, an estimated $911K.
  • Inhibrx made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3256 holding.
  • Squarepoint first reported a position in Inhibrx in Q3 2024 and has held it in 4 quarters since.
  • Squarepoint's Inhibrx position peaked at $1.05M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.